STAT+: Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more
STAT
MARCH 12, 2025
The agreement covering Zealand’s compound petrelintide, signals renewed efforts by Roche to catch up with obesity market leaders Novo Nordisk and Eli Lilly. billion in upfront cash , STAT writes.
Let's personalize your content